Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, Back D, Winston A.

J Antimicrob Chemother. 2013 Jun;68(6):1348-53. doi: 10.1093/jac/dkt006. Epub 2013 Jan 30.

2.

Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.

Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):167-73. doi: 10.1097/QAI.0b013e3182a03d95.

3.

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.

Antivir Ther. 2010;15(2):213-8. doi: 10.3851/IMP1517.

PMID:
20386076
4.

Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.

Okoli C, Siccardi M, Thomas-William S, Dufty N, Khonyongwa K, Ainsworth J, Watson J, Cook R, Gandhi K, Hickinbottom G, Owen A, Taylor S.

J Antimicrob Chemother. 2012 Mar;67(3):671-4. doi: 10.1093/jac/dkr493. Epub 2011 Dec 15.

5.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
6.

Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.

Furtado J, Madruga JV, Bicudo EL, da Eira M, Lopes MI, Netto EM, Santini-Oliveira M, Leite OH, Machado AA, Tupinambas U, de Andrade Neto JL, Lima MP, Pedro Rde J, Miranda AF, Lewi DS, Santos BR, Portsmouth S, Wajsbrot DB, Cassoli LM.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.

PMID:
23731330
7.

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

Macías J, Recio E, Márquez M, García C, Jiménez P, Merino D, Muñoz L, Pasquau J, Ojeda G, Bancalero P, Chueca N, Pineda JA.

HIV Med. 2014 Aug;15(7):417-24. doi: 10.1111/hiv.12129. Epub 2014 Feb 24.

PMID:
24580801
8.

Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.

Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J.

Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef.

PMID:
23851911
9.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

10.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
11.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
12.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group.

Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.

PMID:
25103176
13.

Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.

Ahmed N, Okoli C, Ainsworth J.

Int J STD AIDS. 2016 Mar;27(4):321-2. doi: 10.1177/0956462415584486. Epub 2015 May 11.

PMID:
25969439
14.

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B.

AIDS. 2007 Jul 11;21(11):1449-55.

PMID:
17589191
15.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jun 16;14(9):F103-10.

PMID:
10894270
16.

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64. doi: 10.1097/QAI.0b013e3181ee3d82.

17.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.

AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.

PMID:
19487905
18.

Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.

Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM.

Antimicrob Agents Chemother. 2011 May;55(5):2290-6. doi: 10.1128/AAC.01046-10. Epub 2011 Mar 7.

19.

Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

Bonjoch A, Pou C, Pérez-Álvarez N, Bellido R, Casadellà M, Puig J, Noguera-Julian M, Clotet B, Negredo E, Paredes R.

J Antimicrob Chemother. 2013 Jun;68(6):1382-7. doi: 10.1093/jac/dks539. Epub 2013 Jan 25.

20.

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A.

J Antimicrob Chemother. 2012 Jan;67(1):206-12. doi: 10.1093/jac/dkr427. Epub 2011 Oct 10.

Items per page

Supplemental Content

Write to the Help Desk